2012
DOI: 10.1016/j.ejca.2012.01.014
|View full text |Cite
|
Sign up to set email alerts
|

Cancer guideline development in Europe: A survey among ECCO members

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 2 publications
0
2
0
Order By: Relevance
“…17 A solution has been proposed by the European Cancer Organization, by which high-quality guidelines are endorsed provided they fulfill minimal quality criteria, including multidisciplinarity, validated methodology, transparent conflict-of-interest policy, and involvement of patient organizations. 18 Another option will be in the future the development of metaguidelines. The term has been recently used to describe the undertaking of collecting recommendations from various sources, then updating and reconciling the differences, in the context of the management of patients with schizophrenia, 19 but can easily be transposed in the field of oncology.…”
Section: Discussionmentioning
confidence: 99%
“…17 A solution has been proposed by the European Cancer Organization, by which high-quality guidelines are endorsed provided they fulfill minimal quality criteria, including multidisciplinarity, validated methodology, transparent conflict-of-interest policy, and involvement of patient organizations. 18 Another option will be in the future the development of metaguidelines. The term has been recently used to describe the undertaking of collecting recommendations from various sources, then updating and reconciling the differences, in the context of the management of patients with schizophrenia, 19 but can easily be transposed in the field of oncology.…”
Section: Discussionmentioning
confidence: 99%
“…Clinical practice guidelines are designed to assist health care professionals (HPs) to provide the most appropriate care for their patients [ 1 ]. Using best available evidence, guideline development is slow and expensive [ 2 ]. Yet, many guidelines are not implemented [ 3 ], with potential benefits for patients lost.…”
Section: Introduction / Aimmentioning
confidence: 99%